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The COVID-19 pandemic and its associated response have disrupted 
essential health services across the globe.[1] In South Africa (SA), as in 
many other countries affected by the pandemic, healthcare resources 
have been shifted away from non-COVID-19 patients to deal with 
the surge in COVID-19 patients.[2] Concern has been raised over 
the impact on morbidity and mortality from diseases that have been 
sidelined in favour of COVID-19.[3]
Cancer diagnosis is one of the essential health services that have 
been negatively affected. Several studies from around the world have 
reported a decline in the number of new cancers diagnosed since the 
start of the pandemic.[4-14] Since the incidence of cancer is expected to 
remain relatively stable over a period of months, this decline can be 
attributed to a delay in cancer diagnosis due to the pandemic. A delay 
in diagnosis is likely to lead to patients presenting at a more advanced 
stage and poorer clinical outcomes.
The anatomical pathology laboratory at our institution is one 
of only two anatomical pathology laboratories that serve the adult 
public healthcare sector in Western Cape Province, SA. We observed 
a substantial decrease in our total pathology caseload during 
the months following the implementation of national lockdown 
restrictions on 26 March 2020, but the exact effect on the number of 
new cancer diagnoses is unknown.
Objectives
To assess the impact of the COVID-19 pandemic and its associated 
response on the number of new cancers diagnosed at our institution 
during the months following the implementation of lockdown 
restrictions.
Methods
We conducted a retrospective laboratory-based audit of common, 
newly diagnosed, non-cutaneous cancers in adults (>18 years of 
age) in specimens registered during the 3-month period of the 
second quarter of the year, from 1 April 2020 to 30 June 2020 
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Background. The COVID-19 pandemic has disrupted cancer diagnostic services. A decline in the number of new cancers being diagnosed 
over a relatively short term implies a delay in diagnosis and subsequent treatment. This delay is expected to have a negative effect on cancer-
related morbidity and mortality. The impact of the pandemic on the number of new cancer diagnoses in our setting is unknown.
Objectives. To assess the impact of COVID-19 on the number of new cancers diagnosed at our institution in the first 3 months following 
the implementation of lockdown restrictions, by focusing on common non-cutaneous cancers.
Methods. A retrospective laboratory-based audit was performed at a large anatomical pathology laboratory in Western Cape Province, 
South Africa. The numbers of new diagnoses for six common cancers (breast, prostate, cervix, large bowel, oesophagus and stomach) from 
1 April 2020 to 30 June 2020 were compared with the corresponding period in 2019.
Results. Histopathological diagnoses for the six cancers combined decreased by 192 (–36.2%), from 531 new cases in the 2019 study period 
to 339 in the corresponding period in 2020. Substantial declines were seen for prostate (–58.2%), oesophageal (–44.1%), breast (–32.9%), 
gastric (–32.6%) and colorectal cancer (–29.2%). The smallest decline was seen in cervical cancer (–7%). New breast cancers diagnosed by 
cytopathology declined by 61.1%.
Conclusions. The first wave of the COVID-19 pandemic and the associated response resulted in a substantial decline in the number of 
new cancer diagnoses, implying a delay in diagnosis. Cancer-related morbidity and mortality is expected to rise as a result, with the greatest 
increase in mortality expected from breast and colorectal cancer.
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(2020  Q2), and compared this with the corresponding period in 
2019 (2019 Q2).
The non-cutaneous cancers in SA with the highest projected 
incidence were selected for the audit: cancer of the breast, prostate, 
uterine cervix, lung and colorectum.[15] In addition, cancer of the 
oesophagus was included because it is currently ranked fifth in terms 
of mortality. Stomach cancer was included because the Western Cape 
is a known hotspot for this cancer in SA.
Cancers of these anatomical sites diagnosed by histopathology were 
identified by searching for Systematized Nomenclature of Medicine 
codes on the laboratory information system. These codes had been 
assigned at the time of diagnosis by the pathologist responsible for the 
case. The electronic pathology reports were accessed and reviewed to 
confirm that the code corresponded to the diagnosis on the report. 
The following cases were excluded: (i) referred cases from outside 
the usual drainage area of the laboratory; (ii) in situ carcinoma where 
no invasion could be demonstrated; (iii) cases where the diagnosis 
of cancer was uncertain; (iv) recurrent cancer that had already been 
previously diagnosed; and (v) duplicate diagnoses from the same 
anatomical site (only first specimen included).
For breast cancer, in addition to the above cancers diagnosed by 
histopathology, cancers diagnosed on fine-needle aspiration biopsy by 
cytopathology were identified by searching for the malignant breast 
cytology category code. Similar exclusion criteria were applied, but 
breast cancers diagnosed by cytopathology were reported separately 
from breast cancers diagnosed by histopathology (some patients may 
have been diagnosed by both modalities).
We determined the total number of histopathology specimens with 
unique episode numbers registered on the laboratory information 
system during 2020 Q2 and the corresponding periods during the 
preceding 3 years (2017 - 2019) to assess the overall histopathology 
caseload trend over a 4-year period. The number of new cancers for 
the selected anatomical sites were then determined for 2020 Q2 and 
2019 Q2. We compared age at diagnosis, sex (for oesophageal, gastric 
and colorectal cancer) and the level of healthcare facility (central, 
regional and district level and lower) where the diagnostic procedure 
was performed between these two time periods.
Analysis was completed using Stata Statistical Software, release 
10 (StataCorp, USA). Frequency distributions, means and 95% 
confidence intervals (CIs) were calculated where applicable. The time 
period during which diagnoses were made was assessed for bivariate 
association with age at diagnosis, sex (where applicable) and the level 
of the health facility where the diagnostic procedure was performed. 
The t-test for means and χ2 test for proportions were used at a 
significance level of 0.05 (2-sided).
The study received ethical approval from the Stellenbosch Uni ver sity 
Health Research Ethics Committee on 4 November 2020 (ref. no. 
N20/10/065_COVID-19).
Results
The laboratory received histopathology and cytopathology specimens 
from public healthcare facilities distributed over a large geographical 
area that included parts of the City of Cape Town metropolitan area 
and the Cape Winelands, Central Karoo, Garden Route, Overberg 
and West Coast districts. This drainage area is inhabited by an 
estimated 4.5 million people,[16] of whom fewer than 25% are covered 
by medical insurance.[17] Tissue specimens with a diagnosis of cancer 
were received from one central hospital, three regional hospitals, 
24 district hospitals and 8 different community health centres/clinics. 
The laboratory drainage area remained the same for 2019 Q2 and 
2020 Q2.
The number of working days for both periods was the same 
(60 days). The 2020 Q2 period extended over three different COVID-
19 alert levels: level 5 from 1 to 30 April, level 4 from 1 to 31 May and 
level 3 from 1 to 30 June.
The overall histopathology caseload for the second quarter of 
the year remained relatively stable for the 3 preceding years, with 
7 503, 8 118 and 8 157 cases in 2017, 2018 and 2019, respectively, but 
decreased dramatically by 3 825 (–46.9%) to 4 332 cases in 2020.
New histopathological diagnoses for six selected cancers combined 
(breast, prostate, uterine cervix, colorectum, oesophagus and stomach) 
decreased by 192 (–36.2%) from 531 in 2019 Q2 to 339 in 2020 Q2. 
Lung cancer had to be excluded from the analysis owing to inability 
to distinguish accurately between primary and secondary tumours 
based on the limited clinical data available in the pathology reports. 
A summary of the results is presented in Table 1. The largest decline 
was seen in prostate cancer (–58.2%) and the smallest in cervical cancer 
(–7%) (Fig. 1). Breast cancers diagnosed by cytopathology declined by 
61.1%. Gastrointestinal cancers (cancer of the oesophagus, stomach 
and colorectum combined) declined by 35.5%. The number of new 
cancers diagnosed per full week is graphically represented in Fig. 2. The 
number of new histopathology diagnoses for the six cancers combined, 
as a percentage of the total histopathology caseload, increased from 
6.5% in 2019 Q2 to 7.8% in 2020 Q2.
The mean age at diagnosis for the six cancers in 2020 was 2 years 
younger than in 2019 (p=0.018). The age difference was most 
pronounced for colorectal cancer, with a mean age of 64 years in 
2019 Q2 and 58 years in 2020 Q2 (p=0.012). The age at diagnosis for 
the other specific cancers did not show any statistically significant 
differences between the study periods.
Table 1. Comparison of cancer diagnoses per site between 2019 Q2 and 2020 Q2
                    New cancer diagnoses Age (years), mean (95% CI)
2019 Q2, n 2020 Q2, n Decrease, n (%) 2019 Q2 2020 Q2 p-value
Breast, histopathology 152 102 50 (32.9) 54 (52 - 67) 57 (54 - 60) 0.149
Breast, cytopathology† 95 37 58 (61.1) NA NA -
Prostate 122 51 71 (58.2) 67 (66 - 68) 65 (63 - 67) 0.171
Uterine cervix 71 66 5 (7) 52 (49 - 55) 51 (48 - 54) 0.643
Colorectal 72 51 21 (29.2) 64 (61 - 67) 58 (54 - 61) 0.012*
Oesophagus 68 38 30 (44.1) 63 (60 - 65) 60 (56 - 66) 0.45
Stomach 46 31 15 (32.6) 61 (58 - 65) 60 (55 - 64) 0.576
Six cancers combined‡ 531 339 192 (36.2) 60 (59 - 61) 58 (57 - 59) 0.018*
Q2 = second quarter of the year, 1 April - 30 June; CI = confidence interval; NA = not available.
*Statistically significant result (p<0.05).
†May show overlap with those diagnosed on histopathology; some breast cancers were diagnosed by both modalities. 
‡Only for histopathological diagnoses; breast cancers diagnosed by cytopathology were not included.
572       June 2021, Vol. 111, No. 6
RESEARCH
There was no statistically significant differ-
ence between the study periods in sex or 
in the level of healthcare facility where the 
diagnostic procedures were performed.
Forty-four of 66 patients with cervical 
cancer (66.7%) diagnosed in 2020 Q2 had 
an abnormal cervical smear cytology result 
during the preceding year.
Sub-analysis of prostate cancers showed 
a decrease of 63.6% in high-risk cancers 
(Grade Groups 4 and 5), in line with the 
decrease of 53.7% in low- and intermediate-
risk cancers (Grade Groups 1 - 3).
Colorectal cancer tended to be diagnosed 
more frequently on resection specimens than 
on biopsy specimens in 2020 Q2 compared 
with 2019 Q2, but this result was not 
statistically significant (odds ratio 1.9; 95% 
CI 0.92 - 3.96; p=0.079). The pathological 
stage of colorectal cancers first diagnosed 
on resection specimens did not show a 
statistically significant difference between 
these periods (p=0.101).
Discussion
We demonstrated a substantial decline in 
newly diagnosed cancers (–36.2%) for six 
common cancers combined in 2020 Q2 
compared with 2019 Q2. Our results echo 
the findings of several studies (using a variety 
of data sources) from around the world 
(Table 2).
There are many possible reasons for this 
decline. In a pulse survey conducted by 
the World Health Organization, the reasons 
provided for the interruption of essential 
health services were a mix of demand and 
supply factors.[1] On the demand side, the 
causes most often mentioned were patients 
not presenting to outpatient care, public 
transport restrictions hindering access, and 
financial difficulties preventing attendance. 
Fear of contracting COVID-19 and mistrust 
were mentioned as additional reasons. 
On the supply side, the most commonly 
mentioned factor was the cancellation of 
elective services. Other factors included 
staff redeployment to provide COVID-
19 relief, insufficient personal protective 
equipment available for healthcare providers, 
unavailability of services due to closure of 
services or health facilities, and interruptions 
in the supply of medical equipment and 
health products.
In our setting, the suspension or de- 
escalation of routine outpatient health 
services appeared to play a major role in 
the decline and may explain some of the 
differences in the decline between specific 
cancers. The large decline in new breast 
cancers diagnosed on cytopathology can in 
part be ascribed to the temporary closure 
of a dedicated fine-needle aspiration clinic. 
Similarly, the decline in prostate cancer 
and gastrointestinal cancers can largely be 
attributed to the substantial de-escalation 
of routine prostate biopsy and endoscopic 
services, respectively. The small decline in the 
number of newly diagnosed cervical cancers 
can be explained by the uninterrupted, albeit 
scaled-down, service of the colposcopy 
clinic at our institution throughout the 
study period. However, outreach colposcopy 
clinics were cancelled. Cervical cancer 
also had the benefit of being part of a 
formal screening programme, which was 
not the case with the other cancers in this 
study. Approximately two-thirds of patients 
diagnosed with cervical cancer in 2020 Q2 
had an abnormal cervical smear result in 
the preceding year, and were therefore likely 
























































2019 Q2         2020 Q2
Fig. 1. Number of new cancers by anatomical site, 2020 Q2 v. 2019 Q2. (Q2 = second quarter of the 
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Fig. 2. Number of new cancers diagnosed by full week of the year for six selected cancers combined, 
2019 v. 2020. Data for weeks 14 and 27 for both years were omitted because these were not full weeks 
and could not be compared directly. (Weeks 15 - 17 = alert level 5; weeks 18 - 21 = alert level 4; weeks 
22 - 26 = alert level 3.)
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colposcopy clinic or a date for an appointment at the start of the 
pandemic. Disruption of the cervical screening programme during 
2020 Q2 is likely to have a negative effect on cervical cancer diagnosis 
after the study period.
The reason for the statistically significant lower age at cancer 
diagnosis in 2020 Q2 compared with 2019 Q2 for the six cancers 
combined and for colorectal cancer individually is not clear. A 
possible explanation is that older patients tended to avoid healthcare 
facilities more than younger patients during the initial phase of the 
pandemic.
Predicting the impact of diagnostic delay on patient outcome is 
complex and dependent on cancer type and stage. In general, a delay 
in diagnosis is likely to result in a delay in treatment, which carries 
the risk of a tumour progressing from being curable to incurable. 
Apart from resulting in avoidable death, an increase in tumour stage 
may also lead to more extensive and complex treatment, potentially 
increasing morbidity and healthcare costs.
Unpublished data from our radiotherapy unit for the third quarter 
of 2020 show a remarkable correlation between the decline in 
new cancer diagnoses in the second quarter and the reduction in 
radiotherapy for three cancers for which patients were likely to receive 
radiotherapy as part of their treatment plan: prostate (–47.9%), breast 
(–23.5%) and cervical cancer (–3%) (Prof. Hannah Simonds, personal 
communication). The correlation between diagnostic decline and 
reduction in administered radiotherapy treatment for these cancers is 
observed despite the influence of other factors, apart from diagnostic 
delays, that may have influenced the administration of radiotherapy.
Several studies have attempted to quantify the effect of diagnostic 
and treatment delays on cancer outcome.[18-23] While it has been 
shown that a delay in surgical treatment for prostate cancer of up 
to 1 year was not associated with adverse oncological outcomes,[22] 
there is concern over the effect of delay on more aggressive cancer 
types. A pre-pandemic cancer registry study from Taiwan on 39 000 
colorectal cancers found that a longer interval (>30 days) from 
diagnosis to the start of treatment was associated with a significantly 
higher risk of death.[23] In the USA, a model considering the effect 
of COVID-19 on cancer screening and treatment for breast and 
colorectal cancer predicted almost 10 000 excess deaths associated 
with these cancers over the next 10 years. A population-based 
modelling study in England estimated >3 000 avoidable deaths and 
an additional ~60 000 total years of life lost from breast, colorectal, 
lung and oesophageal cancer due to diagnostic delays resulting from 
disruption caused by the COVID-19 pandemic.[20]
In SA, for cancers that showed a substantial decline from pre-
pandemic levels, the effect of diagnostic delay on mortality will 
probably be most significant for breast and colorectal cancer. 
Unfortunately, even before the pandemic, most oesophageal and 
gastric cancers were diagnosed at an advanced stage,[24,25] and further 
diagnostic delays will probably not have a significant impact on 
mortality. Nonetheless, it will take longer for these patients to access 
palliative care, which will result in unnecessary morbidity.
The negative impact of COVID-19 on cancer care goes beyond 
cancer diagnosis and includes the disruption of cancer screening, 
treatment and research.[21] Apart from these immediate and direct 
effects on cancer care, economic recessions per se have been shown 
to have a negative impact on cancer care in pre-pandemic studies,[26,27] 
presumably as a consequence of decreased utilisation of preventive 
healthcare.
To minimise the impact of future lockdowns on cancer diagnosis, it 
is essential that outpatient clinics, endoscopy services, mammography 
services and cancer screening programmes continue to function 
uninterrupted at full capacity as far as possible. Increased resources 
Table 2. Summary of studies evaluating the impact of COVID-19 on cancers covered in the current study
Study Country/region Data source Summary of findings
Dinmohamed et al.[4] Netherlands National tumour registry Notable decrease in all cancer diagnoses; effect most 
pronounced for skin cancers
De Vincentiis et al.[5] Italy Anatomical pathology laboratory 
audit
39% decline in cancer diagnoses compared with the average 
in 2018 and 2019
Ferrara et al.[6] Central and 
Northern Italy
Audit at seven anatomical pathology 
laboratories
44.9% decline in cancer diagnoses compared with the 
average in 2018 and 2019
London et al.[7] USA TriNetX Research Network Up to 65.2% month-on-month decrease in new cancer 
diagnoses; breast cancer screenings dropping by 89.2% and 
colorectal cancer screenings by 84.5%
Rutter et al.[8] UK Endoscopy data 58% reduction in endoscopic cancer detection overall, 72% 
reduction for colorectal cancer
Zadnik et al.[9] Slovenia Tumour registry, e-referral system 
and oncological centre data
43% and 29% decrease in new cancer notifications by 
histopathology and clinical departments, respectively 
Kaufman et al.[10] USA Clinical laboratory using ICD-10 
codes
46.4% decrease for six cancers combined
Tsibulak et al.[11] Austria Data from 18 gynaecological 
departments
24 - 49% month-on-month decline in new gynaecological 
and breast cancers
Suárez et al.[12] Spain Colorectal cancer multidisciplinary 
unit
48% decrease in new colorectal cancer diagnoses, higher 
rate of patients diagnosed in the emergency setting
Maluchnik et al.[13] Poland National Health Fund in Poland 33% decrease in issuing of DiLO cards to patients with 
suspected cancer, to access oncological diagnosis and 
treatment
Marques et al.[14] Brazil Brazilian Public Health System 
(DATASUS)
35.5% average decline for all cancers, corresponding to  
~15 000 undiagnosed cases of cancer monthly
ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th revision.
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and staff will be required, in particular to improve capacity for 
endoscopy and mammography services. Public cancer awareness 
campaigns should be considered to provide information about the 
importance of early detection and diagnosis of cancer. Ultimately, 
the urgent and wide-scale roll-out of an effective SARS-CoV-2 
vaccine is required to prevent further waves and lockdowns, protect 
the healthcare system, and reassure patients that it is safe to visit 
healthcare facilities.
One of the limitations of this study is that it was conducted at a 
single institution. From our interaction with pathologists at other 
laboratories, we suspect that our experience parallels that of most 
anatomical pathology practices in SA. Another limitation is that 
we could not provide accurate data for lung cancer, as we did not 
consistently have adequate clinical information on the pathology 
report to classify tumours as primary lung cancers or metastases from 
other organs.
Further studies are necessary to assess changes in the incidence 
of cancer over a longer period of time, including investigating a 
possible rebound effect caused by ‘catching up’ on cancers that had 
a delayed presentation, the effects of further COVID-19 surges, and 
the effects of disruption of cervical cancer screening programmes on 
the subsequent diagnosis of cervical cancer beyond the study period. 
The true impact on stage migration and cancer-specific mortality will 
only be revealed in the next 5 - 10 years.
Conclusions
The first wave of the COVID-19 pandemic and the associated 
response resulted in a substantial decline in the number of new cancer 
diagnoses at our institution, implying a delay in cancer diagnosis and 
treatment. Cancer-related morbidity and mortality in the next 5 - 
10  years is expected to rise as a result of this, with the greatest increase 
in mortality expected from breast and colorectal cancer. The effect 
of COVID-19 restrictions on the morbidity and mortality of non-
COVID-19 diseases such as cancer should be carefully considered to 
minimise the total burden of disease over the long term.
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